Curaleaf Holdings, Inc.

Curaleaf Holdings, Inc. Earnings Recaps

CURA.TO Healthcare 1 recap
Q3 2025 Nov 6, 2025

Curaleaf Holdings reported a modest revenue increase to $320 million in Q3 2025, driven by stable domestic performance and strong international growth, while achieving enhanced margins and maintaining a healthy cash position.

Key takeaways
  • Revenue grew 2% sequentially, with international segment up 12% sequentially and 56% year-over-year.
  • Adjusted gross margins improved to 50%, reflecting a 115 basis point increase.
  • Achieved $69 million in adjusted EBITDA, with a 22% margin despite headwinds from international operations.
  • Strong cultivation improvements led to average flower potency exceeding 30% for the first time.
  • Closed a $100 million revolving credit line to improve financial flexibility and reduce debt obligations.